A diabetes development hits the news every five minutes. Our job at the DDG, is to showcase to you which of these really matter. We think this DreaMed and Medtronic partnership matters. Why? We’ll get there, but first, let’s define the agreement.

Basically, Medtronic bought DreaMed’s CGM algorithm technology. Here’s a excerpt from the previously linked article by news-medical.net, describing the algorithm:

DreaMed Diabetes’s CE approved GlucoSitter™, which is based on the MD-Logic Artificial Pancreas algorithm, is a fully-automated, artificial-pancreas system for controlling glucose levels. The system links the glucose sensor with the insulin pump through computerized control algorithms. It uses data of glucose levels from a continuous glucose sensor, analyzes them and directs the insulin pump to deliver the correct dose of insulin that should be released to the body in order to maintain balanced blood glucose. In effect, the software continuously monitors glucose levels, and defines precisely when and how to adjust insulin levels.

Now, let’s talk importance: (more…)